Skip to main navigation

Close

Who We Are
- About
- Approach
- Our Team
Dynamo Platform
- Integration of Tools
- Motion-Based Drug Design
Our Science
- Publications
- Pipeline
Patients
Investors & Media
Careers
- Culture & Benefits
- Open Positions

399 Binney Street, 2nd Floor

Cambridge, MA 02139

info@relaytx.com

(617) 370-8837

05

Investors & Media

Press Releases

Overview
News & Events
- Press Releases
- Events
Corporate Presentation
Stock Information
Governance
SEC Filings
Responsibility
Investor Resources

Keyword Search

Year

Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026

March 16, 2026

Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

February 26, 2026

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March

February 23, 2026

Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

February 19, 2026

Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

February 4, 2026

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer

February 3, 2026

Who We Are
Dynamo Platform
Our Science
Patients
Careers
Contact
Investors & Media
Our Team

Relay Therapeutics

60 Hampshire Street

Cambridge, MA 02139

info@relaytx.com

(617) 370-8837

© Relay Therapeutics 2026

Privacy Policy Terms of Use